1. Pink Sheet

Moderna CEO Pushes Back On Trump Debate Comments On COVID Vaccine, Offers Own Timeline

 
• By Jessica Merrill

After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.

Business concept - high speed abstract MRT track of motion light for background in tokyo, japan
Moderna outlines COVID-19 development speed • Source: Shutterstock

Moderna, Inc. CEO Stéphane Bancel pushed back on claims by US President Donald Trump that politics is slowing the development of a COVID-19 vaccine, speaking during a fireside chat at the Financial Times Pharma & Biotech Summit on 30 September.

"Nobody, since we started this race against the virus in early January, from any party, from any branch of government from any country has asked us to go faster or to go slower," Bancel said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Global Pharma Guidance Tracker - April 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.